Redhill Biopharma's RHB-107 (Upamostat) Has Been Accepted For Inclusion In U.S. Government-Supported Protect Multinational Platform Trial For Early Covid-19 Outpatient Treatment To Be Conducted In The U.S., Thailand, Ivory Coast, And South Africa
Portfolio Pulse from Benzinga Newsdesk
Redhill Biopharma's RHB-107 (Upamostat) has been accepted for inclusion in a multinational platform trial for early Covid-19 outpatient treatment. The trial, supported by the U.S. Government, will be conducted in the U.S., Thailand, Ivory Coast, and South Africa. The Phase 2 study, predominantly funded by the U.S. Government Department of Defense, has received FDA clearance to start and is estimated to be completed by the end of 2024.
July 31, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Redhill Biopharma's RHB-107 has been accepted for a multinational Covid-19 treatment trial, with a Phase 2 study cleared by the FDA to start. This could potentially boost the company's profile and stock value.
The acceptance of Redhill Biopharma's RHB-107 for a multinational Covid-19 treatment trial, along with the FDA clearance for the Phase 2 study, indicates a positive development for the company. This could potentially increase investor confidence and boost the company's stock value in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100